NASDAQ:BCAB BioAtla (BCAB) Stock Price, News & Analysis $1.74 -0.11 (-5.95%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$1.72▼$1.8850-Day Range$1.17▼$2.0552-Week Range$1.14▼$4.02Volume479,695 shsAverage Volume720,611 shsMarket Capitalization$83.72 millionP/E RatioN/ADividend YieldN/APrice Target$8.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get BioAtla alerts: Email Address BioAtla MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside398.1% Upside$8.67 Price TargetShort InterestBearish9.87% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.51) to ($1.30) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.92 out of 5 starsMedical Sector504th out of 910 stocksBiological Products, Except Diagnostic Industry76th out of 155 stocks 3.5 Analyst's Opinion Consensus RatingBioAtla has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageBioAtla has received no research coverage in the past 90 days.Read more about BioAtla's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.87% of the outstanding shares of BioAtla have been sold short.Short Interest Ratio / Days to CoverBioAtla has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in BioAtla has recently increased by 18.75%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBioAtla does not currently pay a dividend.Dividend GrowthBioAtla does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BCAB. Previous Next 2.4 News and Social Media Coverage News SentimentBioAtla has a news sentiment score of 1.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for BioAtla this week, compared to 1 article on an average week.Search InterestOnly 4 people have searched for BCAB on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added BioAtla to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioAtla insiders have not sold or bought any company stock.Percentage Held by Insiders11.50% of the stock of BioAtla is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions77.23% of the stock of BioAtla is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about BioAtla's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for BioAtla are expected to grow in the coming year, from ($1.51) to ($1.30) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioAtla is -0.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioAtla is -0.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioAtla has a P/B Ratio of 2.68. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about BioAtla's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyWhy billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. Click here for my exclusive video About BioAtla Stock (NASDAQ:BCAB)BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.Read More BCAB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BCAB Stock News HeadlinesSeptember 4 at 10:58 AM | finance.yahoo.comCompanies Like BioAtla (NASDAQ:BCAB) Could Be Quite RiskyAugust 28, 2024 | finance.yahoo.comBioAtla to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 7, 2024 | Deal Maker (Ad)The solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.August 21, 2024 | markets.businessinsider.comBuy Rating for BioAtla: Promising Pipeline and Strategic Partnerships Fuel Optimistic OutlookAugust 15, 2024 | msn.comMichael Burry increases Alibaba stake, halves stock portfolioAugust 15, 2024 | msn.comMichael Burry of ‘The Big Short' increases Alibaba stake, halves stock portfolioAugust 13, 2024 | markets.businessinsider.comReni Benjamin’s Buy Rating for BioAtla: Strong Pipeline and Financial Health Signal Upside PotentialAugust 11, 2024 | seekingalpha.comBioAtla, Inc. (BCAB) Q2 2024 Earnings Call TranscriptSeptember 7, 2024 | Deal Maker (Ad)The solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.August 9, 2024 | markets.businessinsider.comBioatla Reports Second Quarter 2024 Financial Results and Highlights Recent ProgressAugust 9, 2024 | msn.comBCAB Stock Earnings: BioAtla Meets EPS for Q2 2024August 7, 2024 | sg.finance.yahoo.comBioAtla, Inc. (BCAB) stock price, news, quote & history – Yahoo FinanceJuly 29, 2024 | markets.businessinsider.comBioAtla (BCAB) Receives a Buy from J.P. MorganJuly 25, 2024 | globenewswire.comBioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D DayJuly 23, 2024 | markets.businessinsider.comBioAtla Says Its Drug Ozuriftamab Vedotin To Treat SCCHN Got Fast Track DesignationJuly 9, 2024 | 247wallst.com3 Penny Stocks With 735% Average Upside, According to Wall StreetMay 29, 2024 | globenewswire.comBioAtla to Participate in the Jefferies Global Healthcare ConferenceMay 23, 2024 | globenewswire.comBioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual MeetingSee More Headlines Receive BCAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioAtla and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today9/07/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BCAB CUSIPN/A CIK1826892 Webwww.bioatla.com Phone858-558-0708FaxN/AEmployees60Year FoundedN/APrice Target and Rating Average Stock Price Target$8.67 High Stock Price Target$14.00 Low Stock Price Target$5.00 Potential Upside/Downside+398.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.49) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-123,460,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-169.69% Return on Assets-97.52% Debt Debt-to-Equity RatioN/A Current Ratio3.81 Quick Ratio3.81 Sales & Book Value Annual Sales$250,000.00 Price / Sales334.89 Cash FlowN/A Price / Cash FlowN/A Book Value$0.65 per share Price / Book2.68Miscellaneous Outstanding Shares48,116,000Free Float42,583,000Market Cap$83.72 million OptionableOptionable Beta1.06 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. Jay M. Short Ph.D. (Age 66)Co-Founder, CEO & Chairman Comp: $1.13MMr. Richard A. Waldron (Age 70)Senior VP & CFO Comp: $655.94kDr. Eric L. Sievers M.D. (Age 60)Chief Medical Officer Comp: $654.59kMr. Christian J. Vasquez (Age 48)Chief Accounting Officer, Controller and Corporate Secretary Comp: $408.75kMs. Susie MelodySenior Vice President of Human ResourcesDr. Cathy Chang Ph.D.Senior Vice President of Research & DevelopmentDr. Gerhard Frey Ph.D.Senior Vice President of Technology DevelopmentMs. Monica SullivanSenior Vice President of Intellectual Property & ContractsMs. Sheri LydickChief Commercial OfficerDr. Bin ZhangSenior Vice President of Clinical DevelopmentMore ExecutivesKey CompetitorsVoyager TherapeuticsNASDAQ:VYGRNeoleukin TherapeuticsNASDAQ:NLTXSNDLNASDAQ:SNDLOrganogenesisNASDAQ:ORGOLyell ImmunopharmaNASDAQ:LYELView All CompetitorsInsiders & InstitutionsAQR Capital Management LLCBought 636,136 shares on 8/15/2024Ownership: 1.322%Scion Asset Management LLCBought 633,959 shares on 8/15/2024Ownership: 1.318%Point72 Asia Singapore Pte. Ltd.Bought 72,193 shares on 8/15/2024Ownership: 0.150%Bank of Montreal CanBought 143,521 shares on 8/14/2024Ownership: 0.840%XTX Topco LtdSold 19,784 shares on 8/12/2024Ownership: 0.300%View All Insider TransactionsView All Institutional Transactions BCAB Stock Analysis - Frequently Asked Questions How have BCAB shares performed this year? BioAtla's stock was trading at $2.46 at the beginning of 2024. Since then, BCAB stock has decreased by 29.3% and is now trading at $1.74. View the best growth stocks for 2024 here. How were BioAtla's earnings last quarter? BioAtla, Inc. (NASDAQ:BCAB) issued its earnings results on Thursday, August, 8th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.01. When did BioAtla IPO? BioAtla (BCAB) raised $150 million in an initial public offering (IPO) on Wednesday, December 16th 2020. The company issued 9,400,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Jefferies, Credit Suisse and BTIG acted as the underwriters for the IPO. Who are BioAtla's major shareholders? BioAtla's top institutional investors include AQR Capital Management LLC (1.32%), Scion Asset Management LLC (1.32%), Renaissance Technologies LLC (1.30%) and Massachusetts Financial Services Co. MA (1.12%). Insiders that own company stock include Jay M Phd Short, Christian Vasquez, Lawrence Steinman, Sylvia Mcbrinn, Richard A Waldron, Eric Sievers and Scott Andrew Smith. View institutional ownership trends. How do I buy shares of BioAtla? Shares of BCAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BCAB) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioAtla, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioAtla With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
